Literature DB >> 33363034

Role of Specific B-Cell Receptor Antigens in Lymphomagenesis.

Lorenz Thurner1, Sylvia Hartmann2, Frank Neumann1, Markus Hoth3, Stephan Stilgenbauer1, Ralf Küppers4,5, Klaus-Dieter Preuss1, Moritz Bewarder1.   

Abstract

The B-cell receptor (BCR) signaling pathway is a crucial pathway of B cells, both for their survival and for antigen-mediated activation, proliferation and differentiation. Its activation is also critical for the genesis of many lymphoma types. BCR-mediated lymphoma proliferation may be caused by activating BCR-pathway mutations and/or by active or tonic stimulation of the BCR. BCRs of lymphomas have frequently been described as polyreactive. In this review, the role of specific target antigens of the BCRs of lymphomas is highlighted. These antigens have been found to be restricted to specific lymphoma entities. The antigens can be of infectious origin, such as H. pylori in gastric MALT lymphoma or RpoC of M. catarrhalis in nodular lymphocyte predominant Hodgkin lymphoma, or they are autoantigens. Examples of such autoantigens are the BCR itself in chronic lymphocytic leukemia, LRPAP1 in mantle cell lymphoma, hyper-N-glycosylated SAMD14/neurabin-I in primary central nervous system lymphoma, hypo-phosphorylated ARS2 in diffuse large B-cell lymphoma, and hyper-phosphorylated SLP2, sumoylated HSP90 or saposin C in plasma cell dyscrasia. Notably, atypical posttranslational modifications are often responsible for the immunogenicity of many autoantigens. Possible therapeutic approaches evolving from these specific antigens are discussed.
Copyright © 2020 Thurner, Hartmann, Neumann, Hoth, Stilgenbauer, Küppers, Preuss and Bewarder.

Entities:  

Keywords:  B-cell receptor; antigen; antigens of infectious origin; autoreactivity; lymphoma; posttransnational modification

Year:  2020        PMID: 33363034      PMCID: PMC7756126          DOI: 10.3389/fonc.2020.604685

Source DB:  PubMed          Journal:  Front Oncol        ISSN: 2234-943X            Impact factor:   6.244


  224 in total

1.  Activating L265P mutations of the MYD88 gene are common in primary central nervous system lymphoma.

Authors:  Manuel Montesinos-Rongen; Elzbieta Godlewska; Anna Brunn; Otmar D Wiestler; Reiner Siebert; Martina Deckert
Journal:  Acta Neuropathol       Date:  2011-10-22       Impact factor: 17.088

2.  DEK in the synovium of patients with juvenile idiopathic arthritis: characterization of DEK antibodies and posttranslational modification of the DEK autoantigen.

Authors:  Nirit Mor-Vaknin; Ferdinand Kappes; Amalie E Dick; Maureen Legendre; Catalina Damoc; Seagal Teitz-Tennenbaum; Roland Kwok; Elisa Ferrando-May; Barbara S Adams; David M Markovitz
Journal:  Arthritis Rheum       Date:  2011-02

3.  Hypermorphic mutation of phospholipase C, γ2 acquired in ibrutinib-resistant CLL confers BTK independency upon B-cell receptor activation.

Authors:  Ta-Ming Liu; Jennifer A Woyach; Yiming Zhong; Arletta Lozanski; Gerard Lozanski; Shuai Dong; Ethan Strattan; Amy Lehman; Xiaoli Zhang; Jeffrey A Jones; Joseph Flynn; Leslie A Andritsos; Kami Maddocks; Samantha M Jaglowski; Kristie A Blum; John C Byrd; Jason A Dubovsky; Amy J Johnson
Journal:  Blood       Date:  2015-05-13       Impact factor: 22.113

4.  Identification of Epstein-Barr virus proteins as putative targets of the immune response in multiple sclerosis.

Authors:  Sabine Cepok; Dun Zhou; Rajneesh Srivastava; Stefan Nessler; Susanne Stei; Konrad Büssow; Norbert Sommer; Bernhard Hemmer
Journal:  J Clin Invest       Date:  2005-04-14       Impact factor: 14.808

5.  Association of the autoimmune disease scleroderma with an immunologic response to cancer.

Authors:  Christine G Joseph; Erika Darrah; Ami A Shah; Andrew D Skora; Livia A Casciola-Rosen; Fredrick M Wigley; Francesco Boin; Andrea Fava; Chris Thoburn; Isaac Kinde; Yuchen Jiao; Nickolas Papadopoulos; Kenneth W Kinzler; Bert Vogelstein; Antony Rosen
Journal:  Science       Date:  2013-12-05       Impact factor: 47.728

Review 6.  IL-10 and IL-10 receptor defects in humans.

Authors:  Erik-Oliver Glocker; Daniel Kotlarz; Christoph Klein; Neil Shah; Bodo Grimbacher
Journal:  Ann N Y Acad Sci       Date:  2011-12       Impact factor: 5.691

7.  V(H) gene sequences from primary central nervous system lymphomas indicate derivation from highly mutated germinal center B cells with ongoing mutational activity.

Authors:  A R Thompsett; D W Ellison; F K Stevenson; D Zhu
Journal:  Blood       Date:  1999-09-01       Impact factor: 22.113

8.  Chronic lymphocytic leukaemia is driven by antigen-independent cell-autonomous signalling.

Authors:  Marcus Dühren-von Minden; Rudolf Übelhart; Dunja Schneider; Thomas Wossning; Martina P Bach; Maike Buchner; Daniel Hofmann; Elena Surova; Marie Follo; Fabian Köhler; Hedda Wardemann; Katja Zirlik; Hendrik Veelken; Hassan Jumaa
Journal:  Nature       Date:  2012-09-13       Impact factor: 49.962

9.  Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes.

Authors:  Bjoern Chapuy; Chip Stewart; Andrew J Dunford; Jaegil Kim; Atanas Kamburov; Robert A Redd; Mike S Lawrence; Margaretha G M Roemer; Amy J Li; Marita Ziepert; Annette M Staiger; Jeremiah A Wala; Matthew D Ducar; Ignaty Leshchiner; Ester Rheinbay; Amaro Taylor-Weiner; Caroline A Coughlin; Julian M Hess; Chandra S Pedamallu; Dimitri Livitz; Daniel Rosebrock; Mara Rosenberg; Adam A Tracy; Heike Horn; Paul van Hummelen; Andrew L Feldman; Brian K Link; Anne J Novak; James R Cerhan; Thomas M Habermann; Reiner Siebert; Andreas Rosenwald; Aaron R Thorner; Matthew L Meyerson; Todd R Golub; Rameen Beroukhim; Gerald G Wulf; German Ott; Scott J Rodig; Stefano Monti; Donna S Neuberg; Markus Loeffler; Michael Pfreundschuh; Lorenz Trümper; Gad Getz; Margaret A Shipp
Journal:  Nat Med       Date:  2018-04-30       Impact factor: 53.440

Review 10.  Management of adverse events associated with idelalisib treatment: expert panel opinion.

Authors:  Steven E Coutré; Jacqueline C Barrientos; Jennifer R Brown; Sven de Vos; Richard R Furman; Michael J Keating; Daniel Li; Susan M O'Brien; John M Pagel; Martin H Poleski; Jeff P Sharman; Nai-Shun Yao; Andrew D Zelenetz
Journal:  Leuk Lymphoma       Date:  2015-05-19
View more
  5 in total

Review 1.  Management of Extranodal Marginal Zone Lymphoma: Present and Upcoming Perspectives.

Authors:  Dominic Kaddu-Mulindwa; Lorenz Thurner; Konstantinos Christofyllakis; Moritz Bewarder; Igor Age Kos
Journal:  Cancers (Basel)       Date:  2022-06-19       Impact factor: 6.575

Review 2.  Pathobiology and Therapeutic Relevance of GSK-3 in Chronic Hematological Malignancies.

Authors:  Alberto M Martelli; Francesca Paganelli; Camilla Evangelisti; Francesca Chiarini; James A McCubrey
Journal:  Cells       Date:  2022-05-31       Impact factor: 7.666

3.  Editorial: New Insights Into the Complexity of Tumor Immunology in B-Cell Malignancies: Disease Biology and Signaling.

Authors:  Jérôme Paggetti; Martina Seiffert; Etienne Moussay
Journal:  Front Oncol       Date:  2021-12-15       Impact factor: 6.244

Review 4.  The Biology of Ocular Adnexal Marginal Zone Lymphomas.

Authors:  Patricia Johansson; Anja Eckstein; Ralf Küppers
Journal:  Cancers (Basel)       Date:  2022-02-28       Impact factor: 6.639

5.  Antibiotic and glucocorticoid-induced recapitulated hematological remission in acute myeloid leukemia: A case report and review of literature.

Authors:  Xiao-Yun Sun; Xiao-Dong Yang; Xiao-Qiu Yang; Bo Ju; Nuan-Nuan Xiu; Jia Xu; Xi-Chen Zhao
Journal:  World J Clin Cases       Date:  2022-08-06       Impact factor: 1.534

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.